TY - JOUR
AU - Wilkinson, Tom
AU - De Soyza, Anthony
AU - Carroll, Miles W.
AU - Chalmers, James D.
AU - Crooks, Michael G
AU - Griffiths, Gareth
AU - Shankar-Hari, Manu
AU - Ho, Ling-Pei
AU - Horsley, Alex
AU - Kell, Chris
AU - Lara, Beatriz
AU - Mishra, Biswa
AU - Moate, Rachel
AU - Page, Clive
AU - Pandya, Hitesh
AU - Raw, Jason
AU - Reid, Fred
AU - Saralaya, Dinesh
AU - Scott, Ian C
AU - Siddiqui, Salman
AU - Ustianowski, Andy
AU - van Zuydam, Natalie
AU - Woodcock, Ashley
AU - Singh, Dave
PY - 2023
DA - August
TI - A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: Accord-2
JO - ERJ Open Research
DO - https://doi.org/10.1183/23120541.00249-2023
AB - BACKGROUND: Increased serum interleukin (IL)-33 predicts poor outcomes in patients hospitalised with coronavirus disease 2019 (COVID-19). We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving outcomes in ACCORD-2 (EudraCT: 2020-001736-95).
PB - European Respiratory Society
UR - https://discovery.dundee.ac.uk/en/publications/e3b741e7-df8e-469f-a833-84cb6b92cd96
KW - Coronavirus (COVID-19)
KW - Hospital care
ER